amerithroid: a desiccated thyroid extract (DTE) prescription medication¹
DTEs were the first treatment for hypothyroidism²
These products contained both thyroxine (T4) and triiodothyronine (T3). They led the market until the 1970s, when DTE quality issues and key scientific advances changed the treatment paradigm. Physicians began to favor synthetics, which may still be the right choice for many of your patients.²˒³
1.5 million patients and counting currently take DTE⁴
meet your health-focused patient
meet your health-focused patient
A 35- to 65-year-old female is proactive about her health and reads labels carefully. She is an early adopter who values quality and consistency.
A 35- to 65-year-old female is proactive about her health and reads labels carefully. She is an early adopter who values quality and consistency.
get to know your frustrated patient
get to know your frustrated patient
A 25-year-old+ female who takes levothyroxine daily, as directed. Her labs are “normal,” but she continues to struggle with weight gain and fatigue. She’s actively suffering and ready to learn about another option.
A 25-year-old+ female who takes levothyroxine daily, as directed. Her labs are “normal,” but she continues to struggle with weight gain and fatigue. She’s actively suffering and ready to learn about another option.
“In 35 years of thyroid practice, I’ve found that treatment decisions are highly individual. I can confidently say that patients deserve a choice of treatment for their hypothyroidism.”⁵
—Richard L. Shames, MD
amerithroid: designed to eliminate DTE quality concerns
Backed by the legacy of Jerome Stevens Pharmaceuticals (JSP)—the family-owned company that earned the first FDA approval for levothyroxine tablets—Oliva Therapeutics is uniquely qualified to provide consistent, quality DTE therapy for your patients with hypothyroidism:⁶
![](data:image/svg+xml,<svg display="block" id="1410198439" role="presentation" viewBox="0 0 333 329" xmlns="http://www.w3.org/2000/svg"><g fill="transparent" height="236.01786053510875px" id="TY86WLVUZ" transform="translate(38.971 46.982)" width="256.0292756346907px"><path d="M 0.133 200.072 L 0.133 203.599 C 43.636 122.48 125.522 73.103 125.522 73.103 C 19.965 155.505 24.124 227.646 24.124 227.646 C 135.118 288.245 256.029 0 256.029 0 C -14.261 47.132 0.133 200.072 0.133 200.072" fill="rgb(51, 51, 153)" height="236.01786053510878px" id="QSNgwbaET" transform="translate(0 0)" width="256.0292756346907px"/></g></svg>)
Product quality is ensured within a regularly FDA-inspected facility
Consistent potency is achieved to USP standards for both the active ingredient and finished product
Sourced and made in the United States with visible quality control in the form of a distinct Oliva leaf imprint on every tablet
Amerithroid is being developed with the FDA’s evolving requirements in mind, with U.S.-sourced active pharmaceutical ingredient (API) and full traceability
Usually results in normal TSH and T4 levels, after 2-3 weeks¹
References
References: 1. Amerithroid Thyroid Tablets, USP [package insert]. Ridgewood, NJ: Oliva Therapeutics, LLC; 02/2025. 2. McAninch EA, Bianco AC. The history and future of treatment of hypothyroidism. Ann Intern Med. 2016;164(1):50-56. doi:10.7326/M15-1799 3. Werneck de Castro JP, Fonseca TL, Ueta CB, et al. Differences in hypothalamic type 2 deiodinase ubiquitination explain localized sensitivity to thyroxine. J Clin Invest. 2015;125(2):769-781. doi:10.1172/JCI77588 4. AACE statement on the FDA’s actions to address unapproved thyroid medications. American Association of Clinical Endocrinology. Published September 4, 2025. Accessed July 7, 2026. https://pro.aace.com/recent-news-and-updates/aace-statement-fdas-actions-address-unapproved-thyroid-medications. 5. Data on File, Oliva Therapeutics. 6. U.S. Food and Drug Administration. Levothyroxine sodium products enforcement of August 14, 2001 compliance date and submission of new applications. Published July 2001. Accessed July 7, 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/levothyroxine-sodium-products-enforcement-august-14-2001-compliance-date-and-submission-new
References
References: 1. Amerithroid Thyroid Tablets, USP [package insert]. Ridgewood, NJ: Oliva Therapeutics, LLC; 02/2025. 2. McAninch EA, Bianco AC. The history and future of treatment of hypothyroidism. Ann Intern Med. 2016;164(1):50-56. doi:10.7326/M15-1799 3. Werneck de Castro JP, Fonseca TL, Ueta CB, et al. Differences in hypothalamic type 2 deiodinase ubiquitination explain localized sensitivity to thyroxine. J Clin Invest. 2015;125(2):769-781. doi:10.1172/JCI77588 4. AACE statement on the FDA’s actions to address unapproved thyroid medications. American Association of Clinical Endocrinology. Published September 4, 2025. Accessed July 7, 2026. https://pro.aace.com/recent-news-and-updates/aace-statement-fdas-actions-address-unapproved-thyroid-medications. 5. Data on File, Oliva Therapeutics. 6. U.S. Food and Drug Administration. Levothyroxine sodium products enforcement of August 14, 2001 compliance date and submission of new applications. Published July 2001. Accessed July 7, 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/levothyroxine-sodium-products-enforcement-august-14-2001-compliance-date-and-submission-new
References
References: 1. Amerithroid Thyroid Tablets, USP [package insert]. Ridgewood, NJ: Oliva Therapeutics, LLC; 02/2025. 2. McAninch EA, Bianco AC. The history and future of treatment of hypothyroidism. Ann Intern Med. 2016;164(1):50-56. doi:10.7326/M15-1799 3. Werneck de Castro JP, Fonseca TL, Ueta CB, et al. Differences in hypothalamic type 2 deiodinase ubiquitination explain localized sensitivity to thyroxine. J Clin Invest. 2015;125(2):769-781. doi:10.1172/JCI77588 4. AACE statement on the FDA’s actions to address unapproved thyroid medications. American Association of Clinical Endocrinology. Published September 4, 2025. Accessed July 7, 2026. https://pro.aace.com/recent-news-and-updates/aace-statement-fdas-actions-address-unapproved-thyroid-medications. 5. Data on File, Oliva Therapeutics. 6. U.S. Food and Drug Administration. Levothyroxine sodium products enforcement of August 14, 2001 compliance date and submission of new applications. Published July 2001. Accessed July 7, 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/levothyroxine-sodium-products-enforcement-august-14-2001-compliance-date-and-submission-new
Note that DTE products, including amerithroid, have not been reviewed by the FDA for safety or efficacy.
Indications and Usage
Thyroid Tablets, USP are indicated for:
Replacement or supplemental therapy in hypothyroidism of any etiology (except transient hypothyroidism during recovery from subacute thyroiditis)
TSH suppression in the management of certain goiters and in thyroid cancer
contraindications
Uncorrected adrenal cortical insufficiency
Untreated thyrotoxicosis
Known hypersensitivity to thyroid hormone preparations or excipients
IMPORTANT RISK INFORMATION
BOXED WARNING
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
THYROID HORMONES, ALONE OR IN COMBINATION, SHOULD NOT BE USED FOR WEIGHT LOSS OR OBESITY TREATMENT.
IN EUTHYROID PATIENTS, DOSES WITHIN NORMAL HORMONAL REQUIREMENTS ARE INEFFECTIVE FOR WEIGHT REDUCTION.
LARGER DOSES MAY PRODUCE SERIOUS OR LIFE‑THREATENING TOXICITY, PARTICULARLY WHEN USED WITH SYMPATHOMIMETIC AMINES.
Warnings and Precautions
Cardiovascular Risk
Use with extreme caution in:
Patients with coronary artery disease or angina
Elderly patients
Therapy should be initiated at low doses and titrated carefully, as thyroid hormones may precipitate:
Angina
Arrhythmias
Myocardial infarction
Risk of Over‑Replacement (Hyperthyroidism)
Excess dosing may result in symptoms of hyperthyroidism, including:
Palpitations
Tachycardia
Nervousness
Heat intolerance
Liothyronine (T3) content may produce more rapid and pronounced effects
Endocrine Effects
May worsen:
Diabetes mellitus (increased insulin/oral hypoglycemic requirements)
Adrenal insufficiency (must be corrected prior to therapy)
Requires careful monitoring and dose adjustment
Anticoagulant Sensitivity
Thyroid hormones may increase response to oral anticoagulants
Monitor prothrombin time/INR and adjust anticoagulant dose as needed
Special Populations
Pediatric patients: Excess dosing may cause craniosynostosis
Pregnancy: Continue therapy; dose adjustments may be required
Lactation: Use with caution
Adverse Reactions
Adverse reactions are generally due to overdosage and resemble hyperthyroidism:
Palpitations
Tachycardia
Arrhythmias
Nervousness
Insomnia
Tremor
Heat intolerance
Other reactions are rare when properly dosed
Drug Interactions
Decreased absorption:
Cholestyramine (separate dosing by 4–5 hours)
Increased anticoagulant effects
Altered glycemic control with insulin or oral hypoglycemics
Estrogens/oral contraceptives:
May increase thyroid hormone requirements
Dosage and Administration
Dosage must be individualized based on clinical response and laboratory monitoring (TSH, T4, T3)
Typically initiated at low doses and titrated gradually, especially in patients with cardiovascular disease
Administer orally; consistency in administration is important
This is the most important safety information you should know about AMERITHROID®. For more information see full Prescribing Information, including BOXED WARNING.
To report SUSPECTED ADVERSE REACTIONS, contact Oliva Therapeutics, LLC at 1-877-200-6088, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.
All patient and physician images are representative only.
Note that DTE products, including amerithroid, have not been reviewed by the FDA for safety or efficacy.
Indications and Usage
Thyroid Tablets, USP are indicated for:
Replacement or supplemental therapy in hypothyroidism of any etiology (except transient hypothyroidism during recovery from subacute thyroiditis)
TSH suppression in the management of certain goiters and in thyroid cancer
contraindications
Uncorrected adrenal cortical insufficiency
Untreated thyrotoxicosis
Known hypersensitivity to thyroid hormone preparations or excipients
IMPORTANT RISK INFORMATION
BOXED WARNING
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
THYROID HORMONES, ALONE OR IN COMBINATION, SHOULD NOT BE USED FOR WEIGHT LOSS OR OBESITY TREATMENT.
IN EUTHYROID PATIENTS, DOSES WITHIN NORMAL HORMONAL REQUIREMENTS ARE INEFFECTIVE FOR WEIGHT REDUCTION.
LARGER DOSES MAY PRODUCE SERIOUS OR LIFE‑THREATENING TOXICITY, PARTICULARLY WHEN USED WITH SYMPATHOMIMETIC AMINES.
Warnings and Precautions
Cardiovascular Risk
Use with extreme caution in:
Patients with coronary artery disease or angina
Elderly patients
Therapy should be initiated at low doses and titrated carefully, as thyroid hormones may precipitate:
Angina
Arrhythmias
Myocardial infarction
Risk of Over‑Replacement (Hyperthyroidism)
Excess dosing may result in symptoms of hyperthyroidism, including:
Palpitations
Tachycardia
Nervousness
Heat intolerance
Liothyronine (T3) content may produce more rapid and pronounced effects
Endocrine Effects
May worsen:
Diabetes mellitus (increased insulin/oral hypoglycemic requirements)
Adrenal insufficiency (must be corrected prior to therapy)
Requires careful monitoring and dose adjustment
Anticoagulant Sensitivity
Thyroid hormones may increase response to oral anticoagulants
Monitor prothrombin time/INR and adjust anticoagulant dose as needed
Special Populations
Pediatric patients: Excess dosing may cause craniosynostosis
Pregnancy: Continue therapy; dose adjustments may be required
Lactation: Use with caution
Adverse Reactions
Adverse reactions are generally due to overdosage and resemble hyperthyroidism:
Palpitations
Tachycardia
Arrhythmias
Nervousness
Insomnia
Tremor
Heat intolerance
Other reactions are rare when properly dosed
Drug Interactions
Decreased absorption:
Cholestyramine (separate dosing by 4–5 hours)
Increased anticoagulant effects
Altered glycemic control with insulin or oral hypoglycemics
Estrogens/oral contraceptives:
May increase thyroid hormone requirements
Dosage and Administration
Dosage must be individualized based on clinical response and laboratory monitoring (TSH, T4, T3)
Typically initiated at low doses and titrated gradually, especially in patients with cardiovascular disease
Administer orally; consistency in administration is important
This is the most important safety information you should know about AMERITHROID®. For more information see full Prescribing Information, including BOXED WARNING.
To report SUSPECTED ADVERSE REACTIONS, contact Oliva Therapeutics, LLC at 1-877-200-6088, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.
All patient and physician images are representative only.
Note that DTE products, including amerithroid, have not been reviewed by the FDA for safety or efficacy.
Indications and Usage
Thyroid Tablets, USP are indicated for:
Replacement or supplemental therapy in hypothyroidism of any etiology (except transient hypothyroidism during recovery from subacute thyroiditis)
TSH suppression in the management of certain goiters and in thyroid cancer
contraindications
Uncorrected adrenal cortical insufficiency
Untreated thyrotoxicosis
Known hypersensitivity to thyroid hormone preparations or excipients
IMPORTANT RISK INFORMATION
BOXED WARNING
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
THYROID HORMONES, ALONE OR IN COMBINATION, SHOULD NOT BE USED FOR WEIGHT LOSS OR OBESITY TREATMENT.
IN EUTHYROID PATIENTS, DOSES WITHIN NORMAL HORMONAL REQUIREMENTS ARE INEFFECTIVE FOR WEIGHT REDUCTION.
LARGER DOSES MAY PRODUCE SERIOUS OR LIFE‑THREATENING TOXICITY, PARTICULARLY WHEN USED WITH SYMPATHOMIMETIC AMINES.
Warnings and Precautions
Cardiovascular Risk
Use with extreme caution in:
Patients with coronary artery disease or angina
Elderly patients
Therapy should be initiated at low doses and titrated carefully, as thyroid hormones may precipitate:
Angina
Arrhythmias
Myocardial infarction
Risk of Over‑Replacement (Hyperthyroidism)
Excess dosing may result in symptoms of hyperthyroidism, including:
Palpitations
Tachycardia
Nervousness
Heat intolerance
Liothyronine (T3) content may produce more rapid and pronounced effects
Endocrine Effects
May worsen:
Diabetes mellitus (increased insulin/oral hypoglycemic requirements)
Adrenal insufficiency (must be corrected prior to therapy)
Requires careful monitoring and dose adjustment
Anticoagulant Sensitivity
Thyroid hormones may increase response to oral anticoagulants
Monitor prothrombin time/INR and adjust anticoagulant dose as needed
Special Populations
Pediatric patients: Excess dosing may cause craniosynostosis
Pregnancy: Continue therapy; dose adjustments may be required
Lactation: Use with caution
Adverse Reactions
Adverse reactions are generally due to overdosage and resemble hyperthyroidism:
Palpitations
Tachycardia
Arrhythmias
Nervousness
Insomnia
Tremor
Heat intolerance
Other reactions are rare when properly dosed
Drug Interactions
Decreased absorption:
Cholestyramine (separate dosing by 4–5 hours)
Increased anticoagulant effects
Altered glycemic control with insulin or oral hypoglycemics
Estrogens/oral contraceptives:
May increase thyroid hormone requirements
Dosage and Administration
Dosage must be individualized based on clinical response and laboratory monitoring (TSH, T4, T3)
Typically initiated at low doses and titrated gradually, especially in patients with cardiovascular disease
Administer orally; consistency in administration is important
This is the most important safety information you should know about AMERITHROID®. For more information see full Prescribing Information, including BOXED WARNING.
To report SUSPECTED ADVERSE REACTIONS, contact Oliva Therapeutics, LLC at 1-877-200-6088, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.
All patient and physician images are representative only.
Amerithroid is a registered trademark of Oliva Therapeutics and is manufactured by Jerome Stevens Pharmaceuticals, Inc.
© 2026 Oliva Therapeutics. All rights reserved. US-AME-26009-10/26
This site is intended for U.S. healthcare professionals only.
Amerithroid is a registered trademark of Oliva Therapeutics and is manufactured by Jerome Stevens Pharmaceuticals, Inc.
© 2026 Oliva Therapeutics. All rights reserved. US-AME-26009-10/26
This site is intended for U.S. healthcare professionals only.
Amerithroid is a registered trademark of Oliva Therapeutics and is manufactured by Jerome Stevens Pharmaceuticals, Inc.
© 2026 Oliva Therapeutics. All rights reserved. US-AME-26009-10/26
This site is intended for U.S. healthcare professionals only.
Note that DTE products, including amerithroid, have not been reviewed by the FDA for safety or efficacy.
Indications and Usage
Thyroid Tablets, USP are indicated for:
Replacement or supplemental therapy in hypothyroidism of any etiology (except transient hypothyroidism during recovery from subacute thyroiditis)
TSH suppression in the management of certain goiters and in thyroid cancer
IMPORTANT RISK INFORMATION (CONT’D)
contraindications
Uncorrected adrenal cortical insufficiency
Untreated thyrotoxicosis
Known hypersensitivity to thyroid hormone preparations or excipients
IMPORTANT RISK INFORMATION
BOXED WARNING
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
THYROID HORMONES, ALONE OR IN COMBINATION, SHOULD NOT BE USED FOR WEIGHT LOSS OR OBESITY TREATMENT.
IN EUTHYROID PATIENTS, DOSES WITHIN NORMAL HORMONAL REQUIREMENTS ARE INEFFECTIVE FOR WEIGHT REDUCTION.
LARGER DOSES MAY PRODUCE SERIOUS OR LIFE‑THREATENING TOXICITY, PARTICULARLY WHEN USED WITH SYMPATHOMIMETIC AMINES.
Warnings and Precautions
Cardiovascular Risk
Use with extreme caution in:
Patients with coronary artery disease or angina
Elderly patients
Therapy should be initiated at low doses and titrated carefully, as thyroid hormones may precipitate:
Angina
Arrhythmias
Myocardial infarction
Risk of Over‑Replacement (Hyperthyroidism)
Excess dosing may result in symptoms of hyperthyroidism, including:
Palpitations
Tachycardia
Nervousness
Heat intolerance
Liothyronine (T3) content may produce more rapid and pronounced effects
Endocrine Effects
May worsen:
Diabetes mellitus (increased insulin/oral hypoglycemic requirements)
Adrenal insufficiency (must be corrected prior to therapy)
Requires careful monitoring and dose adjustment
Anticoagulant Sensitivity
Thyroid hormones may increase response to oral anticoagulants
Monitor prothrombin time/INR and adjust anticoagulant dose as needed
Special Populations
Pediatric patients: Excess dosing may cause craniosynostosis
Pregnancy: Continue therapy; dose adjustments may be required
Lactation: Use with caution
Adverse Reactions
Adverse reactions are generally due to overdosage and resemble hyperthyroidism:
Palpitations
Tachycardia
Arrhythmias
Nervousness
Insomnia
Tremor
Heat intolerance
Other reactions are rare when properly dosed
Drug Interactions
Decreased absorption:
Cholestyramine (separate dosing by 4–5 hours)
Increased anticoagulant effects
Altered glycemic control with insulin or oral hypoglycemics
Estrogens/oral contraceptives:
May increase thyroid hormone requirements
Dosage and Administration
Dosage must be individualized based on clinical response and laboratory monitoring (TSH, T4, T3)
Typically initiated at low doses and titrated gradually, especially in patients with cardiovascular disease
Administer orally; consistency in administration is important
This is the most important safety information you should know about AMERITHROID®. For more information see full Prescribing Information, including BOXED WARNING.
To report SUSPECTED ADVERSE REACTIONS, contact Oliva Therapeutics, LLC at 1-877-200-6088, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.
All patient and physician images are representative only.
Note that DTE products, including amerithroid, have not been reviewed by the FDA for safety or efficacy.
Indications and Usage
Thyroid Tablets, USP are indicated for:
Replacement or supplemental therapy in hypothyroidism of any etiology (except transient hypothyroidism during recovery from subacute thyroiditis)
TSH suppression in the management of certain goiters and in thyroid cancer
IMPORTANT RISK INFORMATION (CONT’D)
contraindications
Uncorrected adrenal cortical insufficiency
Untreated thyrotoxicosis
Known hypersensitivity to thyroid hormone preparations or excipients
IMPORTANT RISK INFORMATION
BOXED WARNING
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
THYROID HORMONES, ALONE OR IN COMBINATION, SHOULD NOT BE USED FOR WEIGHT LOSS OR OBESITY TREATMENT.
IN EUTHYROID PATIENTS, DOSES WITHIN NORMAL HORMONAL REQUIREMENTS ARE INEFFECTIVE FOR WEIGHT REDUCTION.
LARGER DOSES MAY PRODUCE SERIOUS OR LIFE‑THREATENING TOXICITY, PARTICULARLY WHEN USED WITH SYMPATHOMIMETIC AMINES.
Warnings and Precautions
Cardiovascular Risk
Use with extreme caution in:
Patients with coronary artery disease or angina
Elderly patients
Therapy should be initiated at low doses and titrated carefully, as thyroid hormones may precipitate:
Angina
Arrhythmias
Myocardial infarction
Risk of Over‑Replacement (Hyperthyroidism)
Excess dosing may result in symptoms of hyperthyroidism, including:
Palpitations
Tachycardia
Nervousness
Heat intolerance
Liothyronine (T3) content may produce more rapid and pronounced effects
Endocrine Effects
May worsen:
Diabetes mellitus (increased insulin/oral hypoglycemic requirements)
Adrenal insufficiency (must be corrected prior to therapy)
Requires careful monitoring and dose adjustment
Anticoagulant Sensitivity
Thyroid hormones may increase response to oral anticoagulants
Monitor prothrombin time/INR and adjust anticoagulant dose as needed
Special Populations
Pediatric patients: Excess dosing may cause craniosynostosis
Pregnancy: Continue therapy; dose adjustments may be required
Lactation: Use with caution
Adverse Reactions
Adverse reactions are generally due to overdosage and resemble hyperthyroidism:
Palpitations
Tachycardia
Arrhythmias
Nervousness
Insomnia
Tremor
Heat intolerance
Other reactions are rare when properly dosed
Drug Interactions
Decreased absorption:
Cholestyramine (separate dosing by 4–5 hours)
Increased anticoagulant effects
Altered glycemic control with insulin or oral hypoglycemics
Estrogens/oral contraceptives:
May increase thyroid hormone requirements
Dosage and Administration
Dosage must be individualized based on clinical response and laboratory monitoring (TSH, T4, T3)
Typically initiated at low doses and titrated gradually, especially in patients with cardiovascular disease
Administer orally; consistency in administration is important
This is the most important safety information you should know about AMERITHROID®. For more information see full Prescribing Information, including BOXED WARNING.
To report SUSPECTED ADVERSE REACTIONS, contact Oliva Therapeutics, LLC at 1-877-200-6088, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.
All patient and physician images are representative only.
Note that DTE products, including amerithroid, have not been reviewed by the FDA for safety or efficacy.
Indications and Usage
Thyroid Tablets, USP are indicated for:
Replacement or supplemental therapy in hypothyroidism of any etiology (except transient hypothyroidism during recovery from subacute thyroiditis)
TSH suppression in the management of certain goiters and in thyroid cancer
IMPORTANT RISK INFORMATION (CONT’D)
contraindications
Uncorrected adrenal cortical insufficiency
Untreated thyrotoxicosis
Known hypersensitivity to thyroid hormone preparations or excipients
IMPORTANT RISK INFORMATION
BOXED WARNING
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
THYROID HORMONES, ALONE OR IN COMBINATION, SHOULD NOT BE USED FOR WEIGHT LOSS OR OBESITY TREATMENT.
IN EUTHYROID PATIENTS, DOSES WITHIN NORMAL HORMONAL REQUIREMENTS ARE INEFFECTIVE FOR WEIGHT REDUCTION.
LARGER DOSES MAY PRODUCE SERIOUS OR LIFE‑THREATENING TOXICITY, PARTICULARLY WHEN USED WITH SYMPATHOMIMETIC AMINES.
Warnings and Precautions
Cardiovascular Risk
Use with extreme caution in:
Patients with coronary artery disease or angina
Elderly patients
Therapy should be initiated at low doses and titrated carefully, as thyroid hormones may precipitate:
Angina
Arrhythmias
Myocardial infarction
Risk of Over‑Replacement (Hyperthyroidism)
Excess dosing may result in symptoms of hyperthyroidism, including:
Palpitations
Tachycardia
Nervousness
Heat intolerance
Liothyronine (T3) content may produce more rapid and pronounced effects
Endocrine Effects
May worsen:
Diabetes mellitus (increased insulin/oral hypoglycemic requirements)
Adrenal insufficiency (must be corrected prior to therapy)
Requires careful monitoring and dose adjustment
Anticoagulant Sensitivity
Thyroid hormones may increase response to oral anticoagulants
Monitor prothrombin time/INR and adjust anticoagulant dose as needed
Special Populations
Pediatric patients: Excess dosing may cause craniosynostosis
Pregnancy: Continue therapy; dose adjustments may be required
Lactation: Use with caution
Adverse Reactions
Adverse reactions are generally due to overdosage and resemble hyperthyroidism:
Palpitations
Tachycardia
Arrhythmias
Nervousness
Insomnia
Tremor
Heat intolerance
Other reactions are rare when properly dosed
Drug Interactions
Decreased absorption:
Cholestyramine (separate dosing by 4–5 hours)
Increased anticoagulant effects
Altered glycemic control with insulin or oral hypoglycemics
Estrogens/oral contraceptives:
May increase thyroid hormone requirements
Dosage and Administration
Dosage must be individualized based on clinical response and laboratory monitoring (TSH, T4, T3)
Typically initiated at low doses and titrated gradually, especially in patients with cardiovascular disease
Administer orally; consistency in administration is important
This is the most important safety information you should know about AMERITHROID®. For more information see full Prescribing Information, including BOXED WARNING.
To report SUSPECTED ADVERSE REACTIONS, contact Oliva Therapeutics, LLC at 1-877-200-6088, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.
All patient and physician images are representative only.